Miprosed (Midazolam)

Midazolam binds to a specific site on the GABA‑A receptor complex, acting as a positive allosteric modulator. This enhances the inhibitory effect of GABA, increasing chloride influx into neurons, which leads to sedation, anxiolysis, hypnosis, and anticonvulsant activity.

The dose of Miprosed is individualized by the prescribing clinician based on the indication, patient age, weight, liver function, and other clinical factors. No fixed regimen is provided here; the prescriber determines the appropriate amount.

Safety data for midazolam during pregnancy and lactation are limited. Use is generally reserved for situations where the benefit outweighs potential risk, and it should be prescribed only after careful evaluation by a qualified healthcare professional.

To order Miprosed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miprosed (midazolam) is a short‑acting benzodiazepine, offering faster onset and shorter duration than longer‑acting agents such as diazepam. This makes it preferable for procedural sedation and brief seizure control, whereas diazepam may be chosen for longer‑lasting anxiolysis or muscle relaxation.

Miprosed should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme heat or humidity.

Miprosed is intended for oral administration. The tablet (or oral formulation) should be swallowed whole with water and not chewed or crushed unless specifically instructed by a healthcare professional.

The most serious risks include severe respiratory depression, profound hypotension, paradoxical agitation, and the potential for withdrawal seizures if the drug is stopped abruptly after prolonged use. Patients should be monitored closely, especially when combined with other depressant agents.

Miprosed is contraindicated in individuals with known hypersensitivity to midazolam or other benzodiazepines, in patients with acute narrow‑angle glaucoma, and in those with severe respiratory insufficiency unless under strict medical supervision.